Medical/Pharmaceuticals

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment...

2025-08-25 09:00 2740

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimm...

2025-08-25 08:00 2537

Heartbeats Launches Digital Wellness Platform Led by World-Renowned Heart Specialist Dr. Hosen Kiat

SYDNEY, Aug. 22, 2025 /PRNewswire/ -- In an online world awash with wellness fads and misinformation, one of the world's most cited cardiologists has decided to step in.Dr Hosen Kiat , ranked among the top 1% of clinical researchers worldwide, has launched aYouTube

2025-08-22 13:22 2871

SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health

* Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. * Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biot...

2025-08-21 20:00 3205

BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization

* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization * Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of ant...

2025-08-21 20:00 2840

FDA clearance of Salix® Coronary Plaque module

 Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 /PRNewswire/ -- Artrya Limited (ASX: AYA) ( Artrya or the Company), a medical technology company commerc...

2025-08-21 19:43 2820

Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year

HANGZHOU, China, Aug. 20, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% y...

2025-08-20 21:41 5291

Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.

SHANGHAI, Aug. 20, 2025 /PRNewswire/ -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" i...

2025-08-20 20:49 2966

First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer

HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed b...

2025-08-20 16:11 2229

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received INDclearance from the U.S. Food and Drug Administration (FDA). The clearance enables ...

2025-08-19 22:00 2232

WuXi Biologics Reports Solid 2025 Interim Results

* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% * IFRS Gross profit margin expanded by 3.6% YoY to 42.7% * EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY * Adjusted EBITDA grew 20.6% YoY and adjusted net profit incr...

2025-08-19 20:35 3060

Tigermed Receives MSCI ESG AAA Rating

HANGZHOU, China, Aug. 18, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us a...

2025-08-19 11:15 3698

Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare

DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed$100 Billion in China and Approach $90 Billion Globally by 2030 BEIJING, Aug. 18, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise specializin...

2025-08-18 21:30 3599

LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...

2025-08-18 20:00 3517

GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies

YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-deri...

2025-08-18 12:40 2583

Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

-  Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. -  Combination of a low dose of ASC47 with A...

2025-08-18 08:15 2291

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the ...

2025-08-17 20:01 2979

VARON's Lung Health Awareness Initiative Urges Proactive Steps for Allergy and Flu this Fall Season

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- With allergy and flu season approaching, VARON  is calling on individuals to take preventive measures to protect their lungs. Through its"Every Breath Counts" i...

2025-08-15 23:08 2972

Novel Gene Therapy for ALS cleared for global trials in China and the U.S.

BEIJING, Aug. 15, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today thatChina's National Medical Products Administration (NMPA) has cleared the Investigational...

2025-08-15 19:00 2268

CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights * Cash and bank balances were around RMB1,261 million as of June 30,...

2025-08-15 08:15 4066
1 ... 52535455565758 ... 261